Navigation Links
Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
Date:2/17/2011

NEW YORK, Feb. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets

http://www.reportlinker.com/p0397049/Antivirals-Market-to-2016---Antiretroviral-Agents-and-Combination-Therapies-to-be-Major-Drivers-HIV-and-Hepatitis-C-Markets.html

Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets

SummaryGBI Research has released its latest research "Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets", which essentially provides insights into diabetes therapeutics sales and price forecasts until 2016. The report also examines the global diabetes therapies treatment usage patterns. The report covers the key geographies of the US, the top five countries in the European region and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2016 are included. The report provides an in-depth analysis of HIV, Hepatitis, Herpes and Influenza therapeutic indications, and includes market forecasts and treatment usage patterns for these two therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also presented.

According to the study done by GBI Research, the HIV market is a growing market dominated by the US. The growth rate is likely to decline from 2012 onwards due to the impact of patent expiry of key drugs. However, migration to new branded drugs is likely to minimize the impact of generics, which currently account for approximately 8% of the market. The global HIV therapeutics market is expected to grow at a CAGR of 4.5% between 2008 and 2015.

Scope- Data and analysis on HIV, Hepatitis, Herpes and Influenza therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the diabetes therapeutics market from 2001 to 2009, with forecasts to 2016.

- Market Data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Key drivers and restraints that have had a significant impact on the market.

- Competitive landscape of the global antivirals therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi-Aventis, Takeda Pharmaceuticals, Merck, GlaxoSmithKline, Roche, Bristol Myers Squibb and Gilead.

Reasons to buy- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

To order this report:: Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805) 652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Manufacturing of Solid Dosage Forms - 2011
2. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
3. Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013
4. Reportlinker Adds US Market for PACS, The
5. Reportlinker Adds Global Anti-counterfeit Markets in Food & Pharmaceutical Applications by Geography, Technology Trends and Forecasts (2010-2015)
6. Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015)
7. Reportlinker Adds Analytical Tool - Antibodies and Peptides in Oncology
8. Reportlinker Adds Analytical Tool - Cancer Therapeutic Antibodies
9. Reportlinker Adds European Markets for Minimally Invasive Spinal Devices 2011
10. Reportlinker Adds European Market for Dental Prosthetics and CAD/CAM Devices 2011
11. Reportlinker Adds Cetuximab - Comprehensive patent search
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... CITY, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company") today announced it has entered into a ... Exchange Commission (SEC) fully resolving the SEC,s investigation ... Act (FCPA).  Under the terms of the settlement ... of $12.8 million, including disgorgement, pre-judgment interest and ...
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... --> --> GAAP ... $130.3 million, up $5.1 million or 4.1% from the ... 7.2% from the fourth quarter of 2014. Revenue for ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
(Date:2/5/2016)... ... 05, 2016 , ... Colorize is a web theme package created ... next using Colorize's dynamic moving camera. Colorize is perfect for personal and web related ... environment with 1 to 5 focus points per scene, stage floor scene presets that ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, Las ... continuing medical education (CME) event presented by the Association for Comprehensive Care in ... for ACCORD, whose mission is to provide education, tools, and resources to primary ...
(Date:2/5/2016)... ... 2016 , ... Susan Polk Health Insurance Company recently released a ... see in 2016. To view the report, see below, or visit Susan Polk's ... Luis Obispo seniors who rely on Medicare health insurance and whose monthly income includes ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... Bailey, today announced their partnership and the start of Project HoldSpace. Through the ... disorders affecting approximately 20 percent of youth between the ages of 13 and ...
Breaking Medicine News(10 mins):